Premium
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B‐cell non‐Hodgkin lymphoma
Author(s) -
Dang Nam H.,
Fayad Luis,
McLaughlin Peter,
Romaguara Jorge E.,
Hagemeister Fredrick,
Goy Andre,
Neelapu Sattva,
Samaniego Felipe,
Walker Pamela L.,
Wang Michael,
Rodriguez Maria A.,
Tong Ann T.,
Pro Barbara
Publication year - 2007
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2007.06684.x
Subject(s) - rituximab , medicine , refractory (planetary science) , follicular lymphoma , lymphoma , gastroenterology , cd20 , oncology , biology , astrobiology
Summary Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B‐cell non‐Hodgkin lymphoma patients. Of the 38 evaluable patients, 30 (80%) were rituximab‐refractory. The overall response rate (ORR) was 32%, with six complete responses (CR) and six partial responses (PR). The median time to progression for responders was 8 months (range: 2–36+); two patients with rituximab‐refractory follicular lymphoma were in CR at 25 and 36+ months. The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab‐refractory follicular lymphoma, and 100% in the three patients with rituximab‐sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon.